课题基金 / 基金详情

Safety and potency of a new tuberculosis vaccine delivered by inhaled aerosol to humans

Safety and potency of a new tuberculosis vaccine delivered by inhaled aerosol to humans
通过吸入气雾剂向人体输送新型结核疫苗的安全性和效力
批准号:
356029
负责人:
Smaill Fiona M
金额:
$80.25万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2016
资助国家:
加拿大
项目状态:
已结题
起止时间:
2016-10-01 至 2019-10-01

项目摘要

项目成果

Smaill Fiona M的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
TB remains a leading infectious cause of global morbidity and mortality. The TB epidemic is made even worse by co-infection with HIV and multi-drug resistant bacteria. This occurs despite decades-long use of BCG vaccine and antibiotics to treat infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans
  • 批准号:
    466312
  • 项目类别:
    Operating Grants
  • 资助金额:
    $602.2万
  • 财政年份:
    2022
  • 负责人:
    Smaill Fiona M
  • 依托单位:
A phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans
  • 批准号:
    474606
  • 项目类别:
    Operating Grants
  • 资助金额:
    $150.55万
  • 财政年份:
    2022
  • 负责人:
    Smaill Fiona M
  • 依托单位:
海外基金